Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 82, Issue 1, 2007, Pages 45-52

  Busca, Alessandro ^a   Locatelli, Franco ^a   Marmont, Filippo ^a   Ceretto, Cristina ^a   Falda, Michele ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Gratt versus host disease; Stem cell transplantation; TNF

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CANDIDIASIS; CAUSE OF DEATH; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVALUATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE SEPSIS; HUMAN; ITALY; LUNG ASPERGILLOSIS; MALE; MYCOSIS; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SIDE EFFECT; VIRUS REACTIVATION;

ACUTE DISEASE; ADULT; AGED; BACTERIAL INFECTIONS; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; STEROIDS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 33845938451     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20752     Document Type: Article

References (31)

1. Klingebiel T, Schlegel PG. GVHD: Overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant 1998;21(suppl. 2):S45-S49.
2. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990;75:1024-1030.
3. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991;324:667-674.
4. Ratanatharathorn V, Ayash L, Lazarius HM, Fu J, Uberti JP. Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121-129.
5. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002; 100:415-419.
6. Ritchie D, Seconi J. Wood C, et al. Prospective monitoring of tumor necrosis factor a and interferon γ to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005;11: 706-712.
7. Ellison CA, Bradley DS, Fisher JM. et al. Murine graft-versus-host disease induced using interferon-γ deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia. Immunology 2002;105:63-72.
8. Harlin H, Artz AS, Mahowald M, et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8 + IFN-γ-producing T cells. Bone Marrow Transplant 2004; 33:491-497.
9. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:680-687.
10. Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35:1003-1010.
11. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002;73:665-667.
12. Andolina M, Rabusin M, Maximova N, Di Leo G. Etanercept in graft-versus-host disease. Bone Marrow Transplant 2000;26: 929.
13. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
14. Shulman HM, Sullivan KM, Weiden PL. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-217.
15. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-955.
16. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs-host disease. J Exp Med 1987;166:1280-1289.
17. Coriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004;104: 649-654.
18. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004;89:1352-1359.
19. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev 2000;14:190-204.
20. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1998;72:555-561.
21. Koc S, Leisenring W, Flowers MED, et al. Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100: 48-51.
22. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002;29:719-725.
23. Goldberg D, Jacobsohn D, Margolis J, Chen A, Vogelsang GB. Pentostatin for the treatment of chronic GVHD in children. Blood 2002;100:846a.
24. Busca A, Locatelli F, Moscato D, Falda M. Sirolimus-related toxicity in stem cell transplantation. Biol Blood Marrow Transplant 2005;11:647-649.
25. Willembacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001;112:820-823.
26. Ratanatharathorn V, Ayash L, Reynolds C. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-511.
27. Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica 2003;88:837-839.
28. Bornhauser M, Schuler U, Pörksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999;67:499-504.
29. Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S203-S208.
30. Jacobson DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: A case series. Am Journal Hematol 2003;74:119-124.
31. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: A cohort study. Blood 2003;102:2768-2776.